Evaxion biotech to announce clinical data for the personalized dna cancer vaccine evx-02 at the 2023 american association for cancer research annual meeting (aacr)

Copenhagen, denmark, march 14, 2023 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-powered immunotherapies, today announced that the company will present clinical readout of the phase 1/2a trial of evx-02 at the upcoming 2023 american association for cancer research annual meeting (2023 aacr), taking place from april 14th to april 19th in orlando, florida.
EVAX Ratings Summary
EVAX Quant Ranking